Imatinib

Generic Name: Imatinib

Brand Names: Gleevec, Glivec, Imatinib Teva, Imatinib Accord

Drug Type: Small Molecule

Chemical Formula: C_₂₉H_₃₁N_₇O

CAS Number: 152459-95-5

Unique Ingredient Identifier: BKJ8M8G5HI

Background: Imatinib is a small molecule kinase inhibitor that revolutionized the treatment of cancer, particularly chronic myeloid leukemia, in 2001. It was deemed a "miracle drug" due to its clinical success, as oncologist Dr. Brian noted that "complete hematologic responses were observed in 53 of 54 patients with CML treated with a daily dosage of 300 mg or more and ...

Indication: Imatinib is indicated for the treatment of adult and pediatric chronic myeloid leukemia with Philadelphia chromosome mutation (Ph+) in blast crisis, accelerated phase, or chronic phase after IFN-alpha therapy failure.Additionally, imatinib is also indicated to treat adult and pediatric Ph+ acute lymphoblastic leukemia, adult myelodysplastic/myeloproliferativ...

Associated Conditions: Accelerated Phase Chronic Myelogenous Leukemia (CML), Aggressive Systemic Mastocytosis, Chordomas, Chronic Eosinophilic Leukemia, FIP1L1-PDGFRα fusion kinase status unknown Chronic eosinophilic leukemia, FIP1L1-PDGFRα fusion kinase status unknown Hypereosinophilic syndrome, Gastrointestinal Stromal Tumor (GIST), Hypereosinophilic Syndrome (HES), Metastatic Gastrointestinal Stromal Tumor (GIST), Metastatic Melanoma, Myelodysplastic Syndrome, Myeloproliferative Disorders (MPD), Refractory Acute Lymphoblastic Leukemia (ALL), Blast phase Chronic myeloid leukemia, CKit mutational status unknown Aggressive systemic mastocytosis, Metastatic Dermatofibrosarcoma protuberans, Newly diagnosed Acute Lymphoblastic Leukaemia, Newly diagnosed, chronic phase Chronic myeloid leukemia, Recurrent Dermatofibrosarcoma protuberans, Refractory, chronic phase Chronic myeloid leukemia, Unresectable Gastrointestinal stromal tumor

Associated Therapies: -

Clinical Trials

A Study of Ponatinib Versus Imatinib in Adults With Acute Lymphoblastic Leukemia

Phase 3

Active, not recruiting

Conditions: Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ALL)

Interventions: Drug: Ponatinib
Drug: Imatinib
Drug: Vincristine
Drug: Dexamethasone
Drug: Cytarabine
Drug: Methotrexate
Drug: Prednisone

First Posted Date: 2018-07-17

Last Posted Date: 2024-10-31

Lead Sponsor: Takeda

Target Recruit Count: 245

Registration Number: NCT03589326

Locations: 🇺🇸
Augusta University Georgia Cancer Center, Augusta, Georgia, United States
🇨🇦
Hopital Charles-LeMoyne, Greenfield Park, Quebec, Canada
🇧🇬
University Multiprofile Hospital for Active Treatment Saint Ivan Rilski, Sofia, Sofiya, Bulgaria

and more 89 locations

Study of Efficacy and Safety of Asciminib in Combination With Imatinib in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP)

Phase 2

Active, not recruiting

Conditions: CML
Leukemia, Myeloid Chronic
Hematologic Diseases
Chronic Myelogenous Leukemia

Interventions: Drug: Asciminib add-on
Drug: Asciminib single agent
Drug: Nilotinib
Drug: Imatinib

First Posted Date: 2018-07-06

Last Posted Date: 2024-05-06

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 104

Registration Number: NCT03578367

Locations: 🇺🇸
Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, United States
🇺🇸
Georgia Regents University, Augusta, Georgia, United States
🇬🇧
Novartis Investigative Site, Oxford, United Kingdom

Evaluation of the Therapeutic Effect of HU Pulse Therapy for CML Patients

Phase 3

Conditions: Leukemia, Chronic Myeloid

Interventions: Drug: hydroxyurea
Drug: Imatinib

First Posted Date: 2018-05-03

Last Posted Date: 2018-05-22

Lead Sponsor: First Affiliated Hospital of Harbin Medical University

Target Recruit Count: 60

Registration Number: NCT03515018

Locations: 🇨🇳
the First Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang, China

Effectiveness and Safety Study of Generic Imatinib in Chronic Myeloid Leukemia Patients in Egypt

Completed

Conditions: Philadelphia Chromosome-positive Chronic Myeloid Leukemia in Chronic Phase

Interventions: Drug: Imatinib

First Posted Date: 2018-03-06

Last Posted Date: 2021-02-23

Lead Sponsor: Hikma Pharmaceuticals LLC

Target Recruit Count: 173

Registration Number: NCT03454503

Locations: 🇪🇬
National Cancer Institute (NCI), Cairo, Egypt

Imatinib for Cytomegalovirus Prophylaxis and Treatment After Allogeneic Hematopoietic Stem Cell Transplantation

Phase 2

Terminated

Conditions: Patients Who Have Received Allo-HSCT

Interventions: Drug: Imatinib
Drug: Placebo

First Posted Date: 2017-11-17

Last Posted Date: 2019-09-11

Lead Sponsor: National Taiwan University Hospital

Target Recruit Count: 5

Registration Number: NCT03343600

Locations: 🇨🇳
National Taiwan University Hospital, Taipei, Taiwan
🇨🇳
Tzu Chi General Hospital, Hualien City, Taiwan
🇨🇳
National Cheng Kung Hospital, Tainan, Taiwan

and more 2 locations

A Study to Investigate the Effects of Imatinib on Pulmonary Vascular Dysfunction in a Human Model of Lung Injury

Phase 1

Completed

Conditions: Acute Lung Injury

Interventions: Drug: Imatinib
Drug: Placebo oral capsule

First Posted Date: 2017-11-01

Last Posted Date: 2018-07-13

Lead Sponsor: Exvastat Ltd.

Target Recruit Count: 47

Registration Number: NCT03328117

Locations: 🇬🇧
PAREXEL Early Phase Clinical Unit, London, United Kingdom

KISS Study: Kinase Inhibition With Sprycel Start up

Phase 2

Active, not recruiting

Conditions: Chronic Myeloid Leukemia

Interventions: Drug: Dasatinib
Drug: Imatinib

First Posted Date: 2017-06-20

Last Posted Date: 2023-11-29

Lead Sponsor: University of Auckland, New Zealand

Target Recruit Count: 91

Registration Number: NCT03193281

Locations: 🇳🇿
Dunedin Hospital, Dunedin, New Zealand
🇳🇿
Auckland City Hospital, Auckland, New Zealand
🇳🇿
Taranaki Base Hospital, New Plymouth, New Zealand

and more 6 locations

Exploratory Study of Drug Sensitivity Prediction Software (IRCR-DReSS) With Patient-derived Tumor Cells of Metastatic Gastric Cancer

Phase 2

Completed

Conditions: Stomach Neoplasms

Interventions: Drug: Sunitinib
Drug: Imatinib
Drug: Gefitinib

First Posted Date: 2017-05-30

Last Posted Date: 2022-06-15

Lead Sponsor: Samsung Medical Center

Target Recruit Count: 66

Registration Number: NCT03170180

Locations: 🇰🇷
Samsung Medical Center, Seoul, Korea, Republic of

A Study of Ruxolitinib vs Best Available Therapy (BAT) in Patients With Steroid-refractory Chronic Graft vs. Host Disease (GvHD) After Bone Marrow Transplantation (REACH3)

Phase 3

Completed

Conditions: Graft-versus-host Disease (GVHD)

Interventions: Drug: Ruxolitinib
Drug: Extracorporeal photopheresis (ECP)
Drug: Low-dose methotrexate (MTX)
Drug: Mycophenolate mofetil (MMF)
Drug: mechanistic Target of Rapamycin (mTOR) inhibitors (everolimus or sirolimus)
Drug: Infliximab
Drug: Rituximab
Drug: Pentostatin
Drug: Imatinib
Drug: Ibrutinib

First Posted Date: 2017-04-13

Last Posted Date: 2023-07-18

Lead Sponsor: Incyte Corporation

Target Recruit Count: 330

Registration Number: NCT03112603

Locations: 🇵🇷
Incyte Investigative Site, Ponce, Puerto Rico
🇬🇧
Novartis Investigative Site, Manchester, United Kingdom
🇷🇴
Novartis Investigational Site, Bucharest, Romania

Study of Cemivil® (Imatinib) in Chronic Myeloid Leukemia Patients in Jordan

Completed

Conditions: Chronic Myeloid Leukemia, Chronic Phase

First Posted Date: 2016-11-30

Last Posted Date: 2016-11-30

Lead Sponsor: Hikma Pharmaceuticals LLC

Target Recruit Count: 91

Registration Number: NCT02977312

Locations: 🇯🇴
Al Bashir Hospital, Amman, Jordan
🇯🇴
Jordan University Hospital, Amman, Jordan
🇯🇴
King Hussein Cancer Center, Amman, Jordan

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy